ADC THERAPEUTICS SA (ADCT) Stock Price, Forecast & Analysis
NYSE:ADCT • CH0499880968
ADCT Key Statistics, Chart & Performance
The current stock price of ADCT is 4.04 USD. In the past month the price increased by 16.67%. In the past year, price increased by 134.66%.
ADCT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ADCT. When comparing the yearly performance of all stocks, ADCT is one of the better performing stocks in the market, outperforming 93.56% of all stocks.
ADCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADCT. ADCT has a bad profitability rating. Also its financial health evaluation is rather negative.
ADCT Financial Highlights
Over the last trailing twelve months ADCT reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS increased by 44.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.61% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADCT Forecast & Estimates
12 analysts have analysed ADCT and the average price target is 8.16 USD. This implies a price increase of 101.98% is expected in the next year compared to the current price of 4.04.
For the next year, analysts expect an EPS growth of 13.35% and a revenue growth 7.28% for ADCT
ADCT Ownership
ADCT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 397.113B | ||
| AMGN | AMGEN INC | 17.19 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.74 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.29 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.38 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.56 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.61 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.92 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADCT
Company Profile
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 263 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Company Info
ADC THERAPEUTICS SA
Biopole, route de la Corniche 3B
Epalinges VAUD 1066 CH
CEO: Christopher Martin
Employees: 263
Phone: 41216530200
ADC THERAPEUTICS SA / ADCT FAQ
Can you describe the business of ADC THERAPEUTICS SA?
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 263 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Can you provide the latest stock price for ADC THERAPEUTICS SA?
The current stock price of ADCT is 4.04 USD. The price decreased by -2.18% in the last trading session.
What is the dividend status of ADC THERAPEUTICS SA?
ADCT does not pay a dividend.
What is the ChartMill rating of ADC THERAPEUTICS SA stock?
ADCT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for ADC THERAPEUTICS SA?
The Revenue of ADC THERAPEUTICS SA (ADCT) is expected to grow by 7.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for ADC THERAPEUTICS SA?
ADC THERAPEUTICS SA (ADCT) currently has 263 employees.